Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Johnson & Johnson JNJ

Healthcare  —  Drug Manufacturers General
271.22 0.54 0.20% as of 25 Sep
Market cap
$652.8B
P/E
31.4×
S&P 500 Member Dividend Aristocrat Cash Flow Champion (3y) Revenue Champion (3y) Insider Buys (last 12m)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Johnson & Johnson (JNJ) EV/EBITDA

As of 25 September 2026, Johnson & Johnson (JNJ) trades at a EV/EBITDA of 19.2×. Over the past ten years it has ranged from 9.2× (August 2015) to 21.3× (April 2023); the current reading is higher than 95% of that period. That is above the Drug Manufacturers General industry median of 13.9× and above the Healthcare sector median of 10.4×.

EV/EBITDA, daily

Annual

Period EV/EBITDA Change
FY2025 12.3× (9.41%)
FY2024 13.6× (18.31%)
FY2023 16.6× (4.74%)
FY2022 17.4× 4.16%
FY2021 16.7× (4.60%)
FY2020 17.5× 11.65%
FY2019 15.7× 17.82%
FY2018 13.3× (15.14%)
FY2017 15.7× 30.18%
FY2016 12.1× 10.03%

Quarterly

Period EV/EBITDA Change
Jun 2026 18.0× 3.32%
Mar 2026 17.4× 41.82%
Dec 2025 12.3× 7.50%
Sep 2025 11.4× 8.48%
42 more quarters

Against its own ten years

Low 9.2× High 21.3×
Ten-year median 14.7×
Current reading's percentile 95

EV/EBITDA against peers

Company EV/EBITDA
PFE Pfizer Inc. compare 10.5×
AZN AstraZeneca PLC compare 13.9×
NVS Novartis AG compare 14.0×
AMGN Amgen Inc. compare 16.2×
JNJ Johnson & Johnson 19.2×
ABBV AbbVie Inc. compare 20.8×
MRK Merck & Co., Inc. compare 30.0×
LLY Eli Lilly and Company compare 30.8×
GILD Gilead Sciences, Inc. compare 804×
Drug Manufacturers General industry median 13.9×
Healthcare sector median 10.4×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on JNJ